| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/19/2005 | US20050107363 administering to mammals drugs such as 5,10-dihydro-4,6,8-trihydroxy-10-(3,7,11-trimethyl-trans-2,trans-6,10-dodecatrienyl)-11H-dibenzo[b,e][1,4]diazepin-11-one, as anticarcinogenic agents |
| 05/19/2005 | US20050107362 Indolamid derivatives which possess glycogenphosphorylase inhibitory activity |
| 05/19/2005 | US20050107361 Anticoagulants; improved side effect reduction, pharmacokinetics and bioavailability |
| 05/19/2005 | US20050107359 Crystalline polymorphic and amorphous forms of benazepril hydrochloride |
| 05/19/2005 | US20050107358 Such as 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{[4-(homomorpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-[(S)-(tetrahydrofuran-3-yl)oxy]-quinazoline; inhibiting signal transduction by tyrosine kinases; treating tumoral diseases and benign prostatic hyperplasia, and diseases of lungs and respiratory tract |
| 05/19/2005 | US20050107357 2,4-dioxo-3-quinazolinylaryl sulfonylureas |
| 05/19/2005 | US20050107356 synergistic effect; CB1 receptor antagonist is an azetidine compound of given formula such as 1-[bis(4-chlorophenyl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]-azetidine), and the dopaminergic agent is ropinirole for example |
| 05/19/2005 | US20050107355 Agonists of the kappa opioid receptor for treating gastrointestinal disorders, pain, and pruritus; N-{2-[(S)-3-hydroxy-pyrrolidin-1-yl]-(S)-1-phenyl-ethyl}-N-methyl-2-phenylamino-acetamide |
| 05/19/2005 | US20050107354 Preventive or therapeutic agent for kidney disease |
| 05/19/2005 | US20050107353 Methods of treating lower urinary tract disorders using losigamone |
| 05/19/2005 | US20050107352 Orally administering to a patient having benign prostatic hyperplasia a therapeutically effective amount of an alpha-1 adrenoceptor blocking agent, and a 13-cis-retinoic acid |
| 05/19/2005 | US20050107351 provides for the reduction or elimination of administered ethinyl estradiol in the first phase without a reduction in contraceptive efficacy or an increase in undesired side effects |
| 05/19/2005 | US20050107350 reducing the dosage and unwanted side effects that are present in current treatments; kits |
| 05/19/2005 | US20050107349 Method for the treatment or prevention of respiratory disorders with a cyclooxygenase-2 inhibitor in combination with a muscarinic receptor antagonist and compositions therewith |
| 05/19/2005 | US20050107348 Contacting cells with a zinc-binding compounds, having effective amount of carboxylic acid derivative or hydroxamic acid derivative inhibitor compound; treating cancer, blood disorders, genetic related metabolic disorders; 3-methyl-5-phenyl-2,4-pentadienoic acid |
| 05/19/2005 | US20050107347 Prime ring substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders |
| 05/19/2005 | US20050107346 Synergistic treatment, better effects on solid tumours; with a mixture of a platinum anticancer agents and a taxane, with ionizing radiation therapy |
| 05/19/2005 | US20050107345 Aminoalkylphosphonates and related compounds as edg receptor agonists |
| 05/19/2005 | US20050107344 Bi phosphate containing protonated compound with two end groups; disinfecting surfaces of surgical equipments and skin |
| 05/19/2005 | US20050107343 Pyrrolo[2,3-d]pyrimidin-2-ylamines substituted in the 7th position by a aryl, heteroaryl, alicyclic, or heterocyclic group connected by methyl, C(O) , C(S) , S(O) or SO2; used in the treatment and prevention of various Heat Shock Protein 90 mediated disorders, e.g., proliferative disorders |
| 05/19/2005 | US20050107340 Protein kinase modulators; cancer, diabetes, hepatic cirrhosis, cardiovascular disease such as atherosclerosis, angiogenesis, immunological disease such as autoimmune disease (e.g., AIDS and lupus) and renal disease |
| 05/19/2005 | US20050107339 Diphenylethylene compounds and uses thereof |
| 05/19/2005 | US20050107338 Antiaging nutrients contains at least two components from acetyl-L-carnitine, N-acetyl cysteine, resveratrol, lecithin, and lipoic acid; reducing age-associated DNA damage, cognition activators, prevent hearing loss; Lipoic acid and acetyl-L-carnitine are not administered at same time; synergistic |
| 05/19/2005 | US20050107337 Platinum complexes having antitumor activity |
| 05/19/2005 | US20050107336 Aryl boronic acids for treating obesity |
| 05/19/2005 | US20050107334 Acyloxyalkyl carbamate prodrugs, methods of synthesis and use |
| 05/19/2005 | US20050107333 Use of mannosamine derivatives for the stimulation of neurite growth |
| 05/19/2005 | US20050107331 Derivatives of partially desulphated glycosaminoglycans endowed with antiangiogenic activity and devoid of anticoagulating effect |
| 05/19/2005 | US20050107330 Drug mixture contains a sympathomimetic selected from the group consisting oxymetazoline, xylometazoline, tramazoline, tetryzoline and naphazoline, and glycosaminoglycan of hyaluronic acid; synergistic effect; vasoconstrictor action, detumescent action on the nose mucous membrane |
| 05/19/2005 | US20050107329 Liposome compositions of porphyrin photosensitizers |
| 05/19/2005 | US20050107325 Conjugated lipophilic group with a modified nucleotide is used to target disease gene, cells, tissue, for drug delivery to entrance into tumor cells; ribose sugar of nucleotide is replaced with a cyclic carrier which has at least one attached phosphate or phosphorothioate group; antitumor biodrugs |
| 05/19/2005 | US20050107323 Cardiac arrhythmia treatment methods |
| 05/19/2005 | US20050107321 FLK-1 is a receptor for vascular endothelial growth factor |
| 05/19/2005 | US20050107317 Nucleic acid molecule of the short-chain dehydrogenase gene family, an antibody, an aptamer or receptors, polypeptide encoded thereby; biodrug for treatment of metabolism of triglycerides, metabolic disorders as obesity, eating disorder, cachexia, diabetes mellitus, hypertension, heart disease |
| 05/19/2005 | US20050107311 buffalo milk and human milk have comparable GM1 and polysialo-ganglioside levels; infant formula; pet foods; instant milk |
| 05/19/2005 | US20050107309 Lowering elevated post-prandial blood glucose levels by increasing incretin half-life comprising administering inhibitor of Dipeptidyl Peptidase (DP IV) or enzymes having DP-IV-like activity; insulinotropic effects are enhanced |
| 05/19/2005 | US20050107308 Use of at least one inhibitor of dipeptidyl peptidase IV (DPIV) or DPIV-like enzyme activity for the preparation of a pharmaceutical formulation for lowering blood pressure levels or related disorders in a mammal |
| 05/19/2005 | US20050107306 Treatment of respiratory disease associated with matrix metalloproteases by inhalation of synthetic matrix metalloprotease inhibitors |
| 05/19/2005 | US20050107303 Health feed |
| 05/19/2005 | US20050107291 Compositions and methods for treating or preventing diseases of body passageways |
| 05/19/2005 | US20050107287 Administering cisplatin; drug delivery; reduced dosage to prevent release into systemic circulation; platinum containing compound entrapped in salt crystals; andone or more lipids |
| 05/19/2005 | US20050107277 Polyalkylene polymer compounds and uses thereof |
| 05/19/2005 | US20050107270 Alkyl ethanolamines for the control of mycobacteria in functional fluid |
| 05/19/2005 | US20050107253 Adsorbent for phosphoric acid |
| 05/19/2005 | US20050106724 Self renewing dental follicle tissues for use in generating periodontal ligament like membrane structures; tissue repair and regenerative medicine |
| 05/19/2005 | US20050106679 Leptin proteins |
| 05/19/2005 | US20050106653 Method for the identification of IRS protein kinase inhibitors or agonist |
| 05/19/2005 | US20050106635 Identifying agents that alter thyroid hormone metabolism or cholesterol and lipid metabolism via coxsackie and adenovirus receptor (CAR) for use as tools in treatment of obesity, cholesterolemia and dyslipidemia |
| 05/19/2005 | US20050106611 Lipoprotein associated phospholipase A2, inhibitors thereof and use of the same in diagnosis and therapy |
| 05/19/2005 | US20050106272 Co-beadlet of dha and rosemary and methods of use |
| 05/19/2005 | US20050106269 stimulating increased NO production; neuroprotectant; increased cerebral blood flow |
| 05/19/2005 | US20050106266 docosahexaenoic acid and a calcium compound (carbonate, hydroxide,sulfate) |
| 05/19/2005 | US20050106264 cystic fibrosis, chronic bronchitis, and ciliary dyskinesia; expand or increase the volume of periciliary liquid layer on airway surfaces thereby increase or facilitate cough clearance, mucociliary clearance, and/or gas-liquid dependent clearance of mucous |
| 05/19/2005 | US20050106263 comprises Green Tea leaf extract, Polyphenols, Epigallocatechin Gallate (EGCG) Vitamin E, Folic Acid, Copper (as Amino Acid Chelate), B12, Zinc (as Oxide), Calcium Pantothenate, Niacin, Biotin, Riboflavin and Thiamine |
| 05/19/2005 | US20050106262 colon tumour, gastric tumour, mammary tumour, ovarian tumour, prostate tumour, and renal tumour |
| 05/19/2005 | US20050106261 Rapid reduction of the alcohol level in blood; by use of multivalent transition metal ions and their complexes, and NAD+ which enhance the oxidation reaction |
| 05/19/2005 | US20050106259 GRAS two acid low pH compound consisting of citric and hydrochloric or phosphoric acids |
| 05/19/2005 | US20050106249 Once-a-day, oral, controlled-release, oxycodone dosage forms |
| 05/19/2005 | US20050106248 Extended release venlafaxine formulation |
| 05/19/2005 | US20050106247 Such as capsules/beads of cyclobenzaprine hydrochloride |
| 05/19/2005 | US20050106246 for treating glutamate dehydrogenase deficiency or increase prolyl hydroxylase and lysyl hydroxylase activity or prevent protein glycation characteristic of atheroscloerosis, cataract formation, retinopathy, and aging; longer therapeutic release times |
| 05/19/2005 | US20050106244 Tablets, granules formed by compression |
| 05/19/2005 | US20050106243 Suspending adsorber material selected from celluloses, polyols, sugar derivatives, maltodextrins, cyclodextrins, starches, and/or polydextroses; pressing |
| 05/19/2005 | US20050106241 Undesirable metabolites associated with first pass effect of selegiline, such as amphetamine and methamphetamine; for treatment of Parkinson's disease, Alzheimers's disease; bioavailability |
| 05/19/2005 | US20050106239 Stabilized azithromycin compositions |
| 05/19/2005 | US20050106238 Orodispersible pharmaceutical composition comprising ivabradine |
| 05/19/2005 | US20050106236 5-Ht4partial agonist pharmaceutical compositions |
| 05/19/2005 | US20050106235 Nsaid formulation comprising a granular composition and an extra-granular composition |
| 05/19/2005 | US20050106234 Calcium formate for use as a dietary supplement |
| 05/19/2005 | US20050106231 Liposome-entrapped topoisomerase inhibitors |
| 05/19/2005 | US20050106230 Drug-enhanced adhesion prevention |
| 05/19/2005 | US20050106229 Antiscarring agents; using tranilast |
| 05/19/2005 | US20050106228 Compositions for the treatment and prevention of cancer |
| 05/19/2005 | US20050106225 Fluid medication delivery device |
| 05/19/2005 | US20050106220 Administering gamma-aminobutyric acid receptor antagonist |
| 05/19/2005 | US20050106217 Adjust fatty acid oxidation; stimulating carnitine palmitoyl transferase |
| 05/19/2005 | US20050106216 Oral compositions of fenretinide having increased bioavailability and methods of using the same |
| 05/19/2005 | US20050106212 Using electrochemical mixture of metal compound and bioactive material; contacting substrate |
| 05/19/2005 | US20050106211 Fabrication of drug loaded biodegradable polymer fibers |
| 05/19/2005 | US20050106209 Composition and apparatus for transdermal delivery |
| 05/19/2005 | US20050106206 Application of a therapeutic substance to a tissue location using an expandable medical device |
| 05/19/2005 | US20050106205 Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners |
| 05/19/2005 | US20050106203 Particularly for a drug eluting stent having an acetate-free layer of a thermoplastic polyacrylate, which may be blended with a nonacrylate polymer such as a fluoropolymer or an ethylene-vinyl alcohol copolymer, and a therapeutically active agent such as rapamycin or derivatives |
| 05/19/2005 | US20050106202 Endoparasiticidal gel composition |
| 05/19/2005 | US20050106195 N-octanoyl amino acid composition for slimming the human body |
| 05/19/2005 | US20050106191 Antiseptic bactericides and cosmetics, drugs and foods containing the antiseptic bactericides |
| 05/19/2005 | US20050106189 Pharmaceutical formulation comprising cyclosporin and use thereof |
| 05/19/2005 | US20050106186 Percutaneous preparations |
| 05/19/2005 | US20050106163 Bovine immunization of new born calf against enteric disease |
| 05/19/2005 | US20050106153 mixture of immunoadjuvant in neoplasm; applying stresses to destroy neoplastic tissue; administering immunomoderator ; in situ generation of autologous vaccine |
| 05/19/2005 | US20050106152 Using protein antagonist; amino acid sequence; antisense nucleotide; inducing apoptosis |
| 05/19/2005 | US20050106151 Bacrtericides; viricides; administering antitrypsin; gramnedative, grampositive bacteria; anthrax |
| 05/19/2005 | US20050106143 Collapsin response mediator protein; measurement of gene expression |
| 05/19/2005 | US20050106142 Rheumatic arthritis; hepatitis c virus; autoimmune diseases ; nterfering with forming or binding of such; autoantigen |
| 05/19/2005 | US20050106135 Compositions, kits and treating methods for alteration cell-cell adhesion, transport, or permeation properties of tissues |
| 05/19/2005 | US20050106132 Using polyoxyethylene glycol monooleate; storage stability |
| 05/19/2005 | US20050106122 Absorption enhancing agent |
| 05/19/2005 | US20050106121 Antimicrobial composites, films, labelstocks, and labels |
| 05/19/2005 | US20050106115 Using a dioxaborinane compound |
| 05/19/2005 | US20050104034 Sustaining the biocidal activity of halogenated polystyrene hydantoin beads by adding a halogen compound to water being treated; making potable water; release free halogen at low concentrations for prolonged periods of time for use in water treatment |